| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/01/2001 | WO2001013911A1 Agents inhibiting hypertensive arteriolar disorder |
| 03/01/2001 | WO2001013910A2 Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| 03/01/2001 | WO2001013909A2 Compositions and methods for treating opiate intolerance |
| 03/01/2001 | WO2001013907A2 Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline |
| 03/01/2001 | WO2001013906A2 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 03/01/2001 | WO2001013905A2 Methods for the treatment of mental and vascular disorders |
| 03/01/2001 | WO2001013904A2 Composition comprising a tramadol material and an anticonvulsant drug |
| 03/01/2001 | WO2001013903A2 Treatment of restless leg syndrome with a combination of clonidine and opioid |
| 03/01/2001 | WO2001013902A2 Combination of active agents, said combination containing clonidine and pramipexol |
| 03/01/2001 | WO2001013901A2 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 03/01/2001 | WO2001013900A2 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
| 03/01/2001 | WO2001013897A1 Oral liquid compositions |
| 03/01/2001 | WO2001013895A2 Controlled-release sedative-hypnotic compositions and methods related thereto |
| 03/01/2001 | WO2001013894A1 Gabapentin tablet and method of making with improved physical and chemical characteristics |
| 03/01/2001 | WO2001013892A2 Large porous particles by spray-drying |
| 03/01/2001 | WO2001013891A2 Modulation of release from dry powder formulations |
| 03/01/2001 | WO2001013890A1 Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants |
| 03/01/2001 | WO2001013889A1 Pharmaceutical composition comprising nabumetone |
| 03/01/2001 | WO2001013888A1 Liposome preparations for external use |
| 03/01/2001 | WO2001013887A2 Phospholipin gel |
| 03/01/2001 | WO2001013886A1 Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
| 03/01/2001 | WO2001013885A1 Method to produce powders for pulmonary or nasal administration |
| 03/01/2001 | WO2001013883A1 Pharmaceutical formulation comprising amoxycillin and clavulanate |
| 03/01/2001 | WO2001013873A1 Composition for topical administration comprising 5-methoxypsoralen |
| 03/01/2001 | WO2001013865A1 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 03/01/2001 | WO2001013780A2 Apparatus and method for anesthetizing the cervical region of a female |
| 03/01/2001 | WO2001013743A1 ASPARTIC AND MALIC ACID INHIBITION OF β-GLUCURONIDASE |
| 03/01/2001 | WO2001013733A1 Fat or oil composition |
| 03/01/2001 | WO2001003670A9 Method for controlled production of ultrafine microparticles and nanoparticles |
| 03/01/2001 | WO2001000617A3 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same |
| 03/01/2001 | WO2001000181A3 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 03/01/2001 | WO2000078297A3 Stable xylometazoline and oxymetazoline solution |
| 03/01/2001 | WO2000075365A3 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 03/01/2001 | WO2000073449B1 Dna encoding snorf33 receptor |
| 03/01/2001 | WO2000073270A8 Remedies for periodontal diseases |
| 03/01/2001 | WO2000072885A9 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 03/01/2001 | WO2000071752A3 Assay for the detection of paclitaxel resistant cells in human tumors |
| 03/01/2001 | WO2000071516B1 INHIBITORS OF FACTOR Xa |
| 03/01/2001 | WO2000071146A3 Glutathione reductase for therapy and prophylaxis of aids |
| 03/01/2001 | WO2000071109A3 Pharmaceutical compositions comprising s-(+) -desmethylselegiline for the treatment of withdrawal |
| 03/01/2001 | WO2000068223A8 Ureas and their use as cell adhesion modulators |
| 03/01/2001 | WO2000068209A3 1,5-benzodiazepine derivatives as cck-a receptor agonists |
| 03/01/2001 | WO2000066577A3 Brigded cycloalkanes as thromboxane ligands without blood clotting effects |
| 03/01/2001 | WO2000064422A3 Novel treatment of neurotraumatic conditions with raf inhibitor |
| 03/01/2001 | WO2000064274A9 Fish feed |
| 03/01/2001 | WO2000061141A3 Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| 03/01/2001 | WO2000061115A3 Pharmaceutical formulation comprising amoxycillin |
| 03/01/2001 | WO2000059488A3 Enhanced tissue and subcellular delivery of vitamin e compounds |
| 03/01/2001 | WO2000058270A3 Hsv primase inhibitors |
| 03/01/2001 | WO2000049413A3 Rapid assay for arthropod-borne disease vectors and pathogens |
| 03/01/2001 | WO2000045802A3 Use of (alpha)-d-glucans for promoting cutaneous wound and ulcer healing |
| 03/01/2001 | WO2000030660A3 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 03/01/2001 | WO2000030638A9 Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient |
| 03/01/2001 | WO2000023060A8 Method of treating immunological disorders mediated by t-lymphocytes |
| 03/01/2001 | WO2000023037A8 Two chamber cartridge for atomizers |
| 03/01/2001 | WO2000019993A3 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
| 03/01/2001 | WO1999043314A9 Farnesyl-protein transferase inhibitors |
| 03/01/2001 | WO1998042379A3 Chemically and thermally stable norastemizole formulations |
| 03/01/2001 | WO1998029107A3 Poly(diallylamine)-based bile acid sequestrants |
| 03/01/2001 | DE19941186A1 Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen Sequence-specific DNA recombination in eukaryotic cells |
| 03/01/2001 | DE19941115A1 Neue Benzoxazin- und Bezothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and Bezothiazin derivatives and their use in medicaments |
| 03/01/2001 | DE19941024A1 Wirkstoffpräparat für tierärztliche Applikation und Verfahren zu seiner Herstellung Drug product for veterinary application and process for its production |
| 03/01/2001 | DE19940795A1 Schnellzerfallende Pellets auf der Basis von Chitosan Rapidly disintegrating pellets based on chitosan |
| 03/01/2001 | DE19940794A1 Pharmazeutische Zubereitung Pharmaceutical composition |
| 03/01/2001 | DE19940748A1 Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide Medicament comprising xenogenic oligo- or / and polyribonucleotides |
| 03/01/2001 | DE19940740A1 Pharmazeutische Salze Pharmaceutical Salts |
| 03/01/2001 | DE19940389A1 Selektive Inhibitoren des Urokinase-Plasminogen Aktivators Selective inhibitors of urokinase plasminogen activator |
| 03/01/2001 | DE19940130A1 Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung New effectors of dipeptidyl peptidase IV for topical use |
| 03/01/2001 | DE19940011A1 Alginataufbereitung und deren Verwendung Alginataufbereitung and their use |
| 03/01/2001 | DE19939981A1 Neue Inhibitoren des Integrins alphavß3 New inhibitors of integrin alphavß3 |
| 03/01/2001 | DE19939980A1 Inhibitoren des Integrins alphavbeta¶3¶ Inhibitors of integrin alphavbeta¶3¶ |
| 03/01/2001 | DE19939921A1 Synergistic drug combination preventing age-related diseases, comprises slowing agent, melatonin, dehydroepiandrosterone and non-steroidal antiphlogistic agent |
| 03/01/2001 | DE19939910A1 Neue Verbindungen, die Tryptase-Aktivität hemmen Novel compounds that inhibit tryptase activity |
| 03/01/2001 | DE10036854A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/01/2001 | DE10029562A1 Medicament useful for treating immunological disorders, Alzheimer's disease, diabetes and obesity comprises a nettle extract prepared using an extractant other than water, ethanol and their mixtures |
| 03/01/2001 | CA2715683A1 Synergistic combination |
| 03/01/2001 | CA2384511A1 Substituted chiral allosteric hemoglobin modifiers |
| 03/01/2001 | CA2384197A1 Fatty acid synthase inhibitors |
| 03/01/2001 | CA2383559A1 Inhibitors of binding between proteins and macromolecular ligands |
| 03/01/2001 | CA2383491A1 Large porous particles by spray-drying |
| 03/01/2001 | CA2383371A1 P193 proteins and nucleic acids, and uses thereof |
| 03/01/2001 | CA2383252A1 Treatment of cardiovascular related pathologies |
| 03/01/2001 | CA2383100A1 Aspartic and malic acid inhibition of .beta.-glucuronidase |
| 03/01/2001 | CA2383063A1 Human abc2 transporter and uses thereof |
| 03/01/2001 | CA2382867A1 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| 03/01/2001 | CA2382850A1 Novel inhibitors of the integrin .alpha.v.beta.3 |
| 03/01/2001 | CA2382838A1 Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition |
| 03/01/2001 | CA2382821A1 Modulation of release from dry powder formulations |
| 03/01/2001 | CA2382674A1 Gas1 polypeptides |
| 03/01/2001 | CA2382666A1 Modulation of the blood-brain barrier transporter for leptin |
| 03/01/2001 | CA2382648A1 Drug treatment for restless leg syndrome |
| 03/01/2001 | CA2382561A1 Inhibitors of integrin .alpha.v.beta.3 |
| 03/01/2001 | CA2382527A1 Rar selective retinoid agonists |
| 03/01/2001 | CA2382467A1 Nucleoside pyrophosphate and triphosphate analogs and related compounds as therapeutic agents |
| 03/01/2001 | CA2382311A1 Substituted piperazine derivatives, the preparation thereof and their use as medicaments |
| 03/01/2001 | CA2382300A1 Composition for topical administration comprising 5-methoxypsoralen |
| 03/01/2001 | CA2382295A1 Piperidine alcohols |
| 03/01/2001 | CA2382220A1 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 03/01/2001 | CA2382218A1 Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants |
| 03/01/2001 | CA2382217A1 Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor |